Energy News / Shareholders Foundation, Inc.

NASDAQ:PLSE Investor Alert: Investigation over Potential Wrongdoing at Pulse Biosciences Inc

Via: ReleaseWire

Updated 11:44 AM CDT, Tue, September 11,2018

An investigation on behalf of investors in Pulse Biosciences Inc (NASDAQ:PLSE) shares over potential wrongdoing at Pulse Biosciences Inc was announced.

San Diego, CA -- (SBWIRE) -- 09/11/2018 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Pulse Biosciences Inc.

Investors who purchased shares of Pulse Biosciences Inc (NASDAQ:PLSE) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Pulse Biosciences Inc directors breached their fiduciary duties and caused damage to the company and its shareholders.

Hayward, CA based Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). Shares of Pulse Biosciences Inc (NASDAQ:PLSE) grew from $6.17 per share in early 2017 to as high as $37.60 per share in June 2017.

On September 11, 2017, Pulse Biosciences Inc disclosed "that it has withdrawn its initial application to the United States Food and Drug Administration (FDA) for 510(k) clearance of its PulseTxTM System." Pulse Biosciences Inc further disclosed that the "voluntary withdrawal on September 8, 2017, was the result of the FDA's appropriate request for additional data that could not be provided within the Agency's 90-day review period that would have otherwise ended on September 10, 2017."

On July 31, 2018, Pulse Biosciences Inc disclosed that it had received subpoenas from the U.S. Securities and Exchange Commission requesting documents and information related to an investigation into trading in the company's stock in advance of its September 2017 financing announcement. Pulse Biosciences Inc further revealed that on July 30, 2018, the company received a letter from Nasdaq stating that Pulse Biosciences Inc is not in compliance with Nasdaq's audit committee requirements and has until July 27, 2019 to regain compliance.

Those who purchased shares of Pulse Biosciences Inc (NASDAQ:PLSE), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqplse-investor-alert-investigation-over-potential-wrongdoing-at-pulse-biosciences-inc-1046238.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com